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Abstract
A simple, efficient, and environment friendly protocol for the synthesis of 1,3,5-triarylpyrazole
and 1,3,5-triarylpyrazolines in [bimm][PF6] ionic liquid mediated by Cu(OTf)2 is described. The
reaction protocol gave 1,3,5-triarylpyrazoles in good to high yields (71-84%) via a one-pot
addition–cyclocondensation between chalcones and arylhydrazines, and oxidative aromatization
without requirement for an additional oxidizing reagent. The catalyst can be reused up to four
cycles without much loss in the catalytic activity. The pyrazoles (4a-o) and pyrazolines (3a-n)
were evaluated for antiproliferative activity in SK-OV-3, HT-29, and HeLa human cancer cells
lines. Among all compounds, 3b inhibited cell proliferation of HeLa cells by 80% at a
concentration of 50 μM.
Introduction
Pyrazoles and their derivatives are well recognized as an important class of heterocyclic
compounds that have found extensive use in the pharmaceutical, material, and agrochemical
industries.1 Compounds containing pyrazole moiety have exhibited diverse biological
activities. For example, 4-substituted 1,5-diaryl-1H-pyrazole-3-carboxylate derivatives can
act as cannabinoid-1 (CB1) receptor antagonists,2-7 Iκβ kinase β (IKKβ or IKK-2)
inhibitors,8 and anti-inflammatory agents.9 Pyrazole derivatives have been shown to have
good binding affinity towards estrogen receptor.10-12 Some of the pyrazole derivatives have
been reported to possess anti-depressant, anti-convulsant,13 anti-inflammatory, and anti-
arthritics14 activities. Pyrazole scaffold constitutes the basic framework of several drug
molecules such as celecoxib (a non-steroidal anti-inflammatory drug)14 and rimonabant (an
anorectic antiobesity drug) (Figure 1). Pyrazoles have received considerable attention of
chemists because of their diverse bioactivities. Thus, a number of synthetic strategies have
been developed for their synthesis.15, 16 The most common approach for the synthesis of
substituted pyrazoles is the condensation of α,β-unsaturated carbonyl compounds with
hydrazines. However, this strategy results in the formation of 4,5-dihydro-1H-pyrazoles
(pyrazolines) that need to be further oxidized to corresponding pyrazoles. For this oxidative
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aromatization of pyrazolines to pyrazoles, various reagents have been employed such as
I2,17 Bi(NO3)3.5H2O,18 MnO2,19 DDQ,20 Pd/C,21 NaOEt,22 PhI(OAc)2,23 TBBDA,24 and
ionic liquid.25, 26 However, many of these oxidative methods suffer from relatively high
oxidant loading, use of strong oxidants and chlorinated organic solvents, harsh conditions,
poor yields, and longer reaction time. Thus, development of environmentally benign process
with the use of alternative solvents such as ionic liquids in place of organic solvent and a
catalytic amount of ecofriendly catalyst that avoid harsh oxidizing reagents is highly
desirable.
As part of our ongoing work on the development of novel reaction methodologies using
metal triflates,27-29 and evaluation of small molecules as anticancer agents,29-32 herein we
report copper triflate-mediated protocol for the synthesis of pyrazoles by reaction of
hydrazines with α,β-unsaturated ketones in 1-butyl-3-methylimidazolium
hexafluorophosphate ([bmim][PF6]) ionic liquid (Scheme 1) and evaluation of their anti-
proliferative activity against different cancer cell lines.
Results and discussion
In the standardization experiment, when 1,2-diphenylprop-2-en-1-one (1) and 4-tert-
butylphenylhydrazine hydrochloride (2) were reacted in ethanol under reflux in the presence
of Cu(OTf)2 (20 mole%), 1-(4-tert-butylphenyl)-3,5-diphenyl-4,5-dihydro-1H-pyrazole (3a)
was obtained in 62% yield (Table 1, entry 8). Further optimization of reaction conditions
was carried out by changing solvents, catalysts, and catalyst loading. As shown in Table 1,
the use of 20 mol% Cu(OTf)2 in [bmim][PF6] gave the desired product 4a in excellent yield
(82%) (Table 1, entry 2). When Cu(OTf)2 was replaced with other catalysts such as pTSA,
Sc(OTf)3, Ce(OTf)3, Zn(OTf)2, AgOTf, or Yb(OTf)3, a mixture of 3a and 4a was observed.
Use of Ce(OTf)3 in [bmim][PF6] resulted in 75% yield of 3a along with 10% of 4a whereas
use of pTSA in [bmim][PF6] gave 69% of 3a (Table 1, entry 11-12). There was not much
increase in yield of 4a on changing the amount of Cu(OTf)2 from 20 mol% to 30 mol%.
However, reducing the amount of Cu(OTf)2 to 10 mol% decreased the yield of 4a to 64%
along with the formation of 3a in 15% (Table 1, entries 1-3). These data indicate that
Cu(OTf)2 was involved in aerobic oxidation of 3a to 4a. It is necessary to mention that 4a
was not formed in the absence of Cu(OTf)2 in [bmim[PF6] ionic liquids, and only 3a was
isolated in 20% yield along with starting material and yield of 3a did not increase with
increasing time upto 2h.
The structure of 4a was confirmed by 1H NMR, 13C NMR, and high-resolution mass
spectrometry. In the 1H NMR spectra, a singlet was observed at δ 6.81 for the proton at C4-
position of pyrazole ring along with other protons on aryl substituents. In the 13C NMR, a
peak appeared at δ 104.97 for the C4-carbon of pyrazole ring. Presence of peak at m/z
355.2173 for [M + H]+ ion with molecular formula C25H27N2 + confirmed the structure of
4a. To explore the synthetic scope and versatility of the protocol, a series of arylhydrazines
(2) were reacted with different α,β-carbonyl compounds (1) under the optimal reaction
conditions. The results are summarized in Table 2. Various functional groups, such as F, Cl,
NO2, OCH3, CH3 and −C(CH3)3 on arylhydrazines and chalcones were well tolerated under
these conditions affording corresponding 1,3,5-substituted pyrazoles (4a-o) in good to high
yields (71–84%).
By monitoring the model reaction between 1,2-diphenylprop-2-en-1-one (1) and tert-
butylphenylhydrazine hydrochloride (2) in the presence of 20 mol% Cu(OTf)2 in [bmim]
[PF6] at different time interval it was found that in first 30 minutes pyrazoline (3a) was the
major product, which got oxidized to pyrazole in the reaction as time progresses. We thus
decided to synthesize the pyrazolines using this protocol in order to evaluate them in our
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biological assay. The reaction of 1 and 2 afforded 1,3,5-triarylpyrazolines (3a–o) via a one-
pot addition–cyclocondensation process in good to high yields (60-84%). Several α,β-
unsaturated carbonyl compounds with both electron-rich and electron-deficient arenes were
successfully applied to this reaction. The results of pyrazoline synthesis are summarized in
Table 3. The chemical structures of all synthesized compounds were elucidated by 1H NMR
and 13C NMR spectroscopic data (Supporting information).
Based on the intermediate formed as pyrazoline 3a and structure of the product 4a, the
reaction is proposed to proceed through the sequential steps as shown in Scheme 2. The first
step is believed to be 1,2-addition of hydrazine to chalcone mediated by Cu(OTf)2. The 3-
hydroxypyrazoline (C) undergoes elimination in the presence of Cu(OTf)2 to give 1,3,5-
triarylpyrazoline derivative (3). Oxidative aromatization of 3 in the presence of Cu(OTf)2
yields corresponding 1,3,5-triarylpyrazole (4). We did not observe formation of 4a, when
isolated 3a was treated with Cu(OTf)2 under nitrogen atmosphere. This further confirms that
3a is converted to 4a via oxidation with atmospheric oxygen in presence of Cu(OTf)2. It
appeared that ionic liquid helps in stabilization of charged intermediate generated by
coordination of Cu(OTf)2 to carbonyl of chalcone and thereby increases electrophilicity of
chalcone.
Further, we investigated the possibility of recycling of the catalyst. After performing the first
cycle, the product was extracted with ethyl acetate/hexane mixture, and Cu(OTf)2 in ionic
liquid was properly dried under vacuum. Furthermore, the fresh chalcone and 4-tert-butyl
phenylhydrazine hydrochloride were added to recovered ionic liquid containing Cu(OTf)2
and the reaction was carried out under same conditions. The above procedure was repeated
four times to give 4a in high yields (82, 80, 78, and 79%) without much loss of catalytic
activity(Table 2, footnote b).
To evaluate the anti-cancer activity of synthesized compounds, all derivatives (4a-o and 3a-
n) were evaluated for their inhibitory activity on the proliferation of human ovarian
adenocarcinoma (SK-OV-3), human colon adenocarcinoma (HT-29), and human cervical
adenocarcinoma (HeLa) cells. Doxorubicin (Dox) and DMSO were used as positive and
negative controls, respectively. The antiproliferative activity results of compounds 4a-o and
3a-n at 50 μM after 72 h incubation are shown in Figures 2 and 3, respectively. Figure 2
shows that among all 1,3,5-triarylpyrazoles derivatives (4a-o), 4c, 4e, 4f, 4g, 4h, 4i, and 4k
inhibit the proliferation of HeLa cells by 50%, 55%, 45%, 39%, 54%, 42%, and 50%,
respectively. However, they did not exhibit significant inhibitory potency in HT-29 and SK-
OV-3 cells. 1,3,5-Triarylpyrazolines derivatives (3a-n) showed high to weak
antiproliferative activity against HeLa cells after 72 h incubation. Compounds 3c, 3d, 3e,
3k, 3l, and 3m inhibited the proliferation of HeLa cells by 62%, 50%, 35%, 58%, 23%, and
40%, respectively. 2-Methylsubstituted compound 3b showed the highest potency by 80%
inhibition of HeLa cells. They showed modest to weak potency in SK-OV-3 and HT-29
cells. Among all derivatives, compound 3b showed comparable potency to doxorubicin (10
μmol) in HeLa cells. Further modification on the chemical structure of this derivative could
lead to the synthesis of a promising candidate that selectively target HeLa cells.
Experimental
General
All chemicals were obtained from commercial suppliers and used without further
purification. Melting points were determined in open capillary tubes on a MPA120-
Automated Melting Point apparatus and are uncorrected. NMR spectra were recorded on a
Brucker (300 MHz) NMR spectrometer using CDCl3 as solvent and the chemical shifts were
expressed in ppm. Metal triflates were purchased from Sigma-Aldrich and used as received.
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All other reagents and solvents were purchased from Merck (India), Spectrochem
Chemicals, S. D. Fine Chemicals, India and used without further purification unless
otherwise specified. Reactions were monitored by using thin layer chromatography (TLC)
on 0.2 mm silica gel F254 plates (Merck). The α,β-unsaturated ketones (chalcones) 1 were
prepared by the treatment of an appropriate acetophenone with benzaldehydes in presence of
sodium hydroxide as reported in literature33
Experimental procedure for synthesis of 3 and 4
Chalcone (1.0 mmol), arylhydrazine hydrochloride (1.2 mmol), Cu(OTf)2 (0.2 mmol, 20
mol%) were added to a 10 mL round bottom flask containing [bmim][PF6] ionic liquid (2
mL). The reaction mixture was heated at 130 °C with stirring for 30 min (for 3) or 1-2.5 h
(for 4). After completion of reaction as indicated by TLC, the reaction mixture was extracted
with ethyl acetate-hexane mixture and the solvent was removed under vacuum. The crude
compound was purified by passing through a bed of silica gel (100-200 mesh) to give pure 3
or 4.
1-(4-tert-Butylphenyl)-4,5-dihydro-3,5-diphenyl-1H-pyrazole (3a)—Pale green
solid, m.p. 148-150 °C; 1H NMR (300 MHz, CDCl3) δ 7.71 (d, J = 7.2 Hz, 2H), 7.39 – 7.29
(m, 8H), 7.20 (d, J = 8.7 Hz, 2H), 7.01 (d, J = 8.6 Hz, 2H), 5.19 (dd, J = 12.2, 8.0 Hz, 1H),
3.80 (dd, J = 17.0, 12.4 Hz, 1H), 3.11 (dd, J = 17.0, 8.0 Hz, 1H), 1.25 (s, 9H); 13C NMR (75
MHz, CDCl3) δ 146.30, 142.97, 142.90, 141.92, 132.88, 129.14, 128.53, 128.46, 127.54,
126.00, 125.71, 124.81, 113.14, 65.06, 43.70, 33.96, 31.48; HRMS (ESI) calcd for
C25H27N2 + 355.2169, found 355.2176 [M + H]+.
4,5-Dihydro-3,5-diphenyl-1-o-tolyl-1H-pyrazole (3b)—Brown liquid; 1H NMR (300
MHz, CDCl3) δ 7.70 (d, J = 7.3 Hz, 2H), 7.41 – 7.30 (m, 5H), 7.29 – 7.19 (m, 3H), 7.12 (d, J
= 7.4 Hz, 1H), 7.05 – 6.85 (m, 3H), 5.26 (t, J = 10.8 Hz, 1H), 3.69 (dd, J = 16.5, 11.1 Hz,
1H), 3.19 (dd, J = 16.4, 10.5 Hz, 1H), 2.43 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 148.13,
144.28, 141.00, 132.99, 131.47, 131.25, 128.69, 128.55, 127.66, 126.93, 126.01, 125.65,
123.28, 119.27, 67.66, 42.67, 20.46; HRMS (ESI) calcd for C22H20N2Na+ 335.1519, found
335.1532 [M + Na]+.
1-(3,4-Dichlorophenyl)-4,5-dihydro-3,5-diphenyl-1H-pyrazole (3c)—Pale yellow
solid, m.p. 133-134 °C; 1H NMR (300 MHz, CDCl3) δ 7.71 (d, J = 7.4 Hz, 2H), 7.42 – 7.31
(m, 5H), 7.30 – 7.23 (m, 4H), 7.14 (d, J = 8.9 Hz, 1H), 6.73 (dd, J = 8.9, 2.5 Hz, 1H), 5.22
(dd, J = 12.2, 6.7 Hz, 1H), 3.85 (dd, J = 17.3, 12.3 Hz, 1H), 3.16 (dd, J = 17.3, 6.7 Hz,
1H); 13C NMR (75 MHz, CDCl3) δ 148.22, 144.02, 141.52, 132.65, 132.15, 130.30, 129.35,
129.15, 128.65, 127.98, 125.95, 125.75, 121.59, 114.94, 112.47, 64.18, 43.78; HRMS (ESI)
calcd for C21H17Cl2N2 + 367.0763, found 367.0782 [M + H]+.
1-(3-Chloro-4-methylphenyl)-4,5-dihydro-3,5-diphenyl-1H-pyrazole (3d)—Pale
yellow solid, m.p. 121-122 °C; 1H NMR (300 MHz, CDCl3) δ 7.71 (d, J = 7.2 Hz, 2H), 7.41
– 7.27 (m, 8H), 7.21 (d, J = 2.1 Hz, 1H), 6.95 (d, J = 8.4 Hz, 1H), 6.71 (dd, J = 8.3, 2.2 Hz,
1H), 5.20 (dd, J = 12.3, 7.2 Hz, 1H), 3.82 (dd, J = 17.1, 12.3 Hz, 1H), 3.12 (dd, J = 17.1, 7.2
Hz, 1H), 2.23 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 147.15, 143.90, 142.17, 134.68,
132.52, 130.92, 129.22, 128.77, 128.58, 127.73, 125.93, 125.85, 125.81, 114.08, 111.56,
64.51, 43.65, 19.03; HRMS (ESI) calcd for C22H20ClN2 + 347.1310; found 347.1321 [M +
H]+.
1-(3,4-Dichlorophenyl)-4,5-dihydro-5-(4-methoxyphenyl)-3-phenyl-1H-pyrazole
(3e)—Yellow solid, m.p. 133-134 °C; 1H NMR (300 MHz, CDCl3) δ 7.71 (d, J = 6.5 Hz,
2H), 7.38 (d, J = 7.5 Hz, 3H), 7.29 – 7.24 (m, 1H), 7.16 (t, J = 8.6 Hz, 3H), 6.85 (d, J = 8.6
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Hz, 2H), 6.75 (dd, J = 8.7, 2.7 Hz, 1H), 5.18 (dd, J = 12.1, 6.7 Hz, 1H), 3.83 (dd, J = 9.9, 7.3
Hz, 1H), 3.77 (s, 3H), 3.13 (dd, J = 17.3, 6.7 Hz, 1H); 13C NMR (75 MHz, CDCl3) δ 159.23,
148.23, 144.06, 133.53, 132.60, 132.23, 130.26, 129.10, 128.64, 126.96, 125.92, 121.51,
114.95, 114.67, 112.54, 63.72, 55.29, 43.81, HRMS (ESI) calcd for C22H19Cl2N2O+
397.0869, found 397.0874 [M + H]+.
1-(3-Chloro-4-methylphenyl)-4,5-dihydro-5-(4-methoxyphenyl)-3-phenyl-1H-
pyrazole (3f)—Off white solid, m.p. 120-121 °C; 1H NMR (300 MHz, CDCl3) δ 7.71 (d, J
= 7.1 Hz, 2H), 7.37 (dd, J = 12.8, 5.3 Hz, 3H), 7.23 – 7.17 (m, 3H), 6.96 (d, J = 8.3 Hz, 1H),
6.85 (d, J = 8.4 Hz, 2H), 6.73 (d, J = 6.2 Hz, 1H), 5.16 (dd, J = 12.1, 7.1 Hz, 1H), 3.82 (d, J
= 4.0 Hz, 1H), 3.76 (s, 3H), 3.10 (dd, J = 17.1, 7.1 Hz, 1H), 2.23 (s, 3H); 13C NMR (75
MHz, CDCl3) δ 159.07, 147.17, 143.94, 134.63, 134.21, 132.60, 130.90, 130.05, 128.73,
128.57, 127.05, 125.86, 125.79, 114.55, 114.09, 111.63, 64.04, 55.27, 43.68, 19.03; HRMS
(ESI) calcd for C23H22ClN2O+ 377.1415, found 377.1427 [M + H]+.
1-(3,4-Dichlorophenyl)-4,5-dihydro-5-(3-methoxyphenyl)-3-p-tolyl-1H-pyrazole
(3g)—Off white solid, m.p. 184-185 °C; 1H NMR (300 MHz, CDCl3) δ 7.59 (d, J = 8.1 Hz,
2H), ), 7.30 – 7.10 (m, 5H), ), 6.89 – 6.75 (m, 3H), 6.73 (dd, J = 8.9, 2.6 Hz, 1H), 5.13 (dd, J
= 12.2, 6.9 Hz, 1H), 3.89 – 3.78 (m, 1H), 3.75 (s, 3H), 3.13 (dd, J = 17.2, 6.9 Hz, 1H), 2.37
(s, 3H); 13C NMR (75 MHz, CDCl3) δ 160.36, 148.48, 144.25, 143.36, 139.34, 132.59,
130.44, 130.26, 129.35, 125.93, 121.42, 117.96, 114.88, 113.09, 112.42, 111.36, 64.14,
55.26, 43.85, 21.44; HRMS (ESI) calcd for C23H21Cl2N2O+ 411.1025, found 411.1043 [M
+ H]+.
1-(3,4-Dichlorophenyl)-4,5-dihydro-3,5-di-p-tolyl-1H-pyrazole (3h)—Off white
solid, m.p. 115-116 °C; 1H NMR (300 MHz, CDCl3) δ 7.60 (d, J = 8.1 Hz, 2H), 7.25 (d, J =
2.6 Hz, 1H), 7.21 – 7.16 (m, 2H), 7.13 – 7.11 (m, 4H), 6.73 (dd, J = 8.9, 2.5 Hz, 1H), 5.16
(dd, J = 12.2, 6.7 Hz, 1H), 3.80 (dd, J = 17.2, 12.2 Hz, 1H), 3.11 (dd, J = 17.2, 6.7 Hz, 1H),
2.37 (s, 3H), 2.31 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 148.41, 144.20, 139.27, 138.67,
137.64, 132.57, 130.23, 129.96, 129.44, 129.34, 125.90, 125.69, 121.27, 114.84, 112.41,
63.90, 43.91, 21.43, 21.11; HRMS (ESI) calcd for C23H21Cl2N2 + 395.1076, found
395.1102 [M + H]+.
1-(3-Chloro-4-methylphenyl)-4,5-dihydro-3,5-dip-tolyl-1H-pyrazole (3i)—Pale
yellow solid, m.p. 135-136 °C; 1H NMR (300 MHz, CDCl3) δ 7.59 (d, J = 8.1 Hz, 2H), 7.20
– 7.18 (m, 2H), 7.17 – 7.14 (m, 3H), 7.13 – 7.09 (m, 2H), 6.94 (d, J = 8.4 Hz, 1H), 6.74 –
6.68 (m, 1H), 5.14 (dd, J = 12.1, 7.2 Hz, 1H), 3.77 (dd, J = 17.1, 12.2 Hz, 1H), 3.08 (dd, J =
17.1, 7.2 Hz, 1H), 2.36 (s, 3H), 2.31 (s, 3H), 2.22 (s, 3H); 13C NMR (75 MHz, CDCl3) δ
147.37, 144.12, 139.33, 138.83, 137.33, 134.62, 130.88, 129.84, 129.81, 129.39, 129.28,
128.61, 125.79, 125.78, 125.64, 114.00, 111.51, 64.25, 43.81, 21.41, 21.11, 19.02; HRMS
(ESI) calcd for C24H24ClN2 + 375.1623; found 375.1635 [M + H]+.
1-(4-tert-Butylphenyl)-4,5-dihydro-3,5-di-p-tolyl-1H-pyrazole (3j)—Pale green
solid, m.p. 108-109 °C; 1H NMR (300 MHz, CDCl3) δ 7.59 (d, J = 8.0 Hz, 2H), 7.33 (d, J =
11.0 Hz, 1H), 7.26 – 7.20 (m, 3H),, 7.19 – 7.13 (m, 4H),, 7.01 (d, J = 8.7 Hz, 2H), 5.13 (dd,
J = 12.2, 8.1 Hz, 1H), 3.76 (dd, J = 17.0, 12.3 Hz, 1H), 3.06 (dd, J = 17.0, 8.1 Hz, 1H), 2.36
(s, 3H), 2.32 (s, 3H), 1.25 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 146.54, 143.15, 141.66,
140.13, 138.46, 137.11, 129.76, 129.22, 128.60, 125.93, 125.66, 124.97, 113.07, 64.82,
43.87, 33.94, 31.48, 21.39, 21.12; HRMS (ESI) calcd for C27H31N2 + 383.2482, found
383.2503 [M + H]+.
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1-(4-tert-Butylphenyl)-3-(4-chlorophenyl)-5-(2-fluorophenyl)-4,5-dihydro-1H-
pyrazole (3k)—Pale green solid, m.p. 81-82 °C; 1H NMR (300 MHz, CDCl3) δ 7.63 (d, J
= 8.5 Hz, 2H), 7.33 (d, J = 8.5 Hz, 2H), 7.23 (d, J = 9.1 Hz, 4H), 7.09 (dd, J = 20.6, 9.0 Hz,
2H), 6.99 (d, J = 8.7 Hz, 2H), 5.52 (dd, J = 12.4, 7.5 Hz, 1H), 3.83 (dd, J = 17.1, 12.4 Hz,
1H), 3.05 (dd, J = 17.1, 7.5 Hz, 1H), 1.26 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 161.34 (d,
JC,F = 248.25 Hz), 145.64, 142.36, 134.25, 131.26, 129.22, 128.75, 127.64 (d, JC,F = 3.9
Hz), 126.88 , 125.87 (d, JC,F = 3.8 Hz), 124.84 (d, JC,F = 3.5 Hz), 123.99, 115.80, 115.52,
113.00, 58.19 (d, JC,F = 3.0 Hz), 42.11, 33.99, 31.46; HRMS (ESI) calcd for C25H25ClFN2 +
407.1685, found 407.1712 [M + H]+.
3-(4-Chlorophenyl)-5-(2-fluorophenyl)-4,5-dihydro-1-o-tolyl-1H-pyrazole (3l)—
Off white solid, m.p. 153-154 °C; 1H NMR (300 MHz, CDCl3) δ 7.62 (d, J = 8.3 Hz, 2H),
7.33 (d, J = 8.2 Hz, 3H), 7.22 – 7.12 (m, 2H), 7.05– 6.97 (m, 3H),6.95 – 6.87 (m, 2H), 5.65
(t, J = 10.8 Hz, 1H), 3.73 (dd, J = 16.4, 11.3 Hz, 1H), 3.11 (dd, J = 16.4, 10.3 Hz, 1H), 2.48
(s, 3H); 13C NMR (75 MHz, CDCl3) δ 161.99 (d, JC, F = 244.5 Hz), 147.05, 143.62, 134.29,
131.52 (d, JC,F = 18.7 Hz), 131.08, 129.20 (d, JC, F = 8.2 Hz), 128.75, 128.23 (d, JC,F = 4.0
Hz), 126.82, 126.08, 124.54 (d, JC,F = 3.5 Hz), 123.40, 118.36, 115.60, 115.31, 60.09 (d,
JC,F = 2.5 Hz), 41.0, 20.42; HRMS (ESI) calcd for C22H19ClFN2 + 365.1215, found
365.1208 [M + H]+.
1-(4-tert-Butylphenyl)-4,5-dihydro-3-(4-methoxyphenyl)-5-(4-nitrophenyl)-1H-
pyrazole (3m)—Dark red solid, m.p. 124-125 °C; 1H NMR (300 MHz, CDCl3) δ 8.20 (d, J
= 8.6 Hz, 2H), 7.64 (d, J = 8.7 Hz, 2H), 7.53 (d, J = 8.6 Hz, 2H), 7.21 (d, J = 8.7 Hz, 2H),
6.92 (dd, J = 8.7, 3.7 Hz, 4H), 5.25 (dd, J = 12.2, 8.0 Hz, 1H), 3.90 – 3.79 (m, 1H), 3.83 (s,
3H), 3.06 (dd, J = 17.0, 7.9 Hz, 1H), 1.25 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 160.33,
150.33, 147.43, 146.46, 142.70, 142.39, 127.27, 127.04, 125.87, 125.04, 124.51, 114.09,
113.08, 64.35, 55.36, 43.59, 33.98, 31.44; HRMS (ESI) calcd for C26H28N3O3 + 430.2125,
found 430.2136 [M + H]+.
1-(3-Chloro-4-methylphenyl)-4,5-dihydro-3-(4-methoxyphenyl)-5-(4-
nitrophenyl)-1H-pyrazole (3n)—Dark red solid, m. p. 120-122 °C; 1H NMR (400 MHz,
CDCl3) δ 8.19 (d, J = 6.7 Hz, 2H), 7.64 (d, J = 6.9 Hz, 2H), 7.46 (d, J = 6.9 Hz, 2H), 7.12 (s,
1H), 6.94 (dd, J = 22.2, 7.2 Hz, 3H), 6.62 (d, J = 6.0 Hz, 1H), 5.26 (dd, J = 9.3, 6.0 Hz, 1H),
4.07 – 3.87 (s, 1H), 3.83 (s, 3H), 3.07 (dd, J = 15.8, 5.5 Hz, 1H), 2.23 (s, 3H); 13C NMR
(101 MHz, CDCl3) δ 160.56, 149.55, 147.52, 147.27, 143.74, 134.87, 131.09, 127.43,
126.93, 126.41, 124.66, 124.59, 114.15, 114.02, 111.43, 63.80, 55.38, 43.58, 19.02; HRMS
(ESI) calcd for C23H20ClN3NaO3 + 444.1085, found 444.1108 [M + Na]+.
1-(4-tert-Butylphenyl)-3,5-diphenyl-1H-pyrazole (4a)—Off white solid, m.p.
149-150 °C; 1H NMR (400 MHz, CDCl3) δ 7.92 (d, J = 7.3 Hz, 2H), 7.42 (t, J = 7.5 Hz, H),
7.37 – 7.25 (m, 10H), 6.81 (s, 1H), 1.31 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 151.74,
150.54, 144.30, 137.68, 133.17, 130.73, 128.76, 128.63, 128.46, 128.21, 127.92, 125.87,
125.80, 124.79, 104.97, 34.65, 31.35; HRMS (ESI) calcd for C25H27N2 + 355.2169, found
355.2173 [M + H]+.
3,5-Diphenyl-1-o-tolyl-1H-pyrazole (4b)—Off white solid, m.p. 95-96 °C; 1H NMR
(300 MHz, CDCl3) δ 7.92 (d, J = 7.4 Hz, 2H), 7.42 (t, J = 7.5 Hz, 2H), 7.36 – 7.28 (m, 3H),
7.27 – 7.18 (m, 7H), 6.87 (s, 1H), 2.03 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 151.76,
145.48, 139.56, 135.71, 133.24, 131.11, 130.27, 129.01, 128.65, 128.46, 128.23, 128.14,
127.91, 127.88, 126.68, 125.80, 103.20, 17.72; HRMS (ESI) calcd for C22H19N2 +
311.1543, found 311. 1536 [M + H]+.
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1-(3,4-Dichlorophenyl)-3,5-diphenyl-1H-pyrazole (4c)—Pale yellow liquid; 1H
NMR (300 MHz, CDCl3) δ 7.90 (d, J = 7.3 Hz, 2H), 7.62 (d, J = 2.4 Hz, 1H), 7.44 (t, J = 7.4
Hz, 2H), 7.39 – 7.35 (m, 4H), 7.33 (s, 1H), 7.29 (dd, J = 6.6, 2.9 Hz, 2H), 7.08 (dd, J = 8.6,
2.4 Hz, 1H), 6.81 (s, 1H); 13C NMR (75 MHz, CDCl3) δ 152.62, 144.57, 139.34, 132.93,
132.60, 131.19, 130.30, 130.05, 128.84, 128.79, 128.75, 128.35, 126.71, 125.87, 123.95,
106.05; HRMS (ESI) calcd for C21H15Cl2N2 + 365.0607, found 365. 0589 [M + H]+.
1-(3-Chloro-4-methylphenyl)-3,5-diphenyl-1H-pyrazole (4d)—Off white solid; m.p.
113-114 °C; 1H NMR (300 MHz, CDCl3) δ 7.91 (d, J = 7.3 Hz, 2H), 7.50 (s, 1H), 7.43 (t, J
= 7.3 Hz, 2H), 7.36 – 7.27 (m, 6H), 7.13 (d, J = 8.1 Hz, 1H), 7.04 (d, J = 8.0 Hz, 1H), 6.80
(s, 1H), 2.37 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 152.15, 144.43, 138.87, 135.29, 134.51,
132.90, 130.78, 130.35, 128.76, 128.69, 128.60, 128.52, 128.12, 125.84, 125.69, 123.26,
105.41, 19.74; HRMS (ESI) calcd for C22H18ClN2 + 345.1153, found 345. 1138 [M + H]+.
1-(3,4-Dichlorophenyl)-5-(4-methoxyphenyl)-3-phenyl-1H-pyrazole (4e)—Off
white solid, m.p. 99-100 °C; 1H NMR (300 MHz, CDCl3) δ 7.89 (d, J = 7.4 Hz, 2H), 7.64
(d, J = 2.3 Hz, 1H), 7.43 (t, J = 7.4 Hz, 2H), 7.38 – 7.21 (m, 2H), 7.21 (d, J = 8.6 Hz, 2H),
7.09 (dd, J = 8.6, 2.3 Hz, 1H), 6.89 (d, J = 8.6 Hz, 2H), 6.75 (s, 1H), 3.83 (s, 3H); 13C NMR
(75 MHz, CDCl3) δ 159.98, 152.53, 144.43, 139.47, 132.90, 132.70, 131.07, 130.28, 130.09,
128.72, 128.28, 126.72, 125.84, 123.96, 122.34, 114.23, 105.57, 55.34; HRMS (ESI) calcd
for C22H17Cl2N2O+ 395.0712, found 395.0696 [M + H]+.
1-(3-Chloro-4-methylphenyl)-5-(4-methoxyphenyl)-3-phenyl-1H-pyrazole (4f)—
m.p. 147-148 °C; Off white solid, 1H NMR (300 MHz, CDCl3) δ 7.90 (d, J = 7.3 Hz, 2H),
7.51 (d, J = 1.6 Hz, 1H), 7.42 (t, J = 7.4 Hz, 2H), 7.33 (t, J = 7.2 Hz, 1H), 7.26 – 7.12 (m,
3H), 7.04 (dd, J = 8.1, 1.7 Hz, 1H), 6.87 (d, J = 8.6 Hz, 2H), 6.74 (s, 1H), 3.82 (s, 3H), 2.37
(s, 3H); 13C NMR (75 MHz, CDCl3) δ 159.74, 152.05, 144.28, 138.99, 135.17, 134.49,
132.99, 130.77, 130.04, 128.65, 128.04, 125.82, 125.71, 123.28, 122.71, 114.04, 104.91,
55.30, 19.73; HRMS (ESI) calcd for C23H20ClN2O+ 375.1259, found 375.1273 [M + H]+.
1-(3,4-Dichlorophenyl)-5-(3-methoxyphenyl)-3-p-tolyl-1H-pyrazole (4g)—Off
white solid, m.p. 135-136 °C; 1H NMR (300 MHz, CDCl3) δ 7.79 (d, J = 7.8 Hz, 2H), 7.64
(d, J = 1.7 Hz, 1H), 7.35 (d, J = 8.6 Hz, 1H), 7.29 – 7.21 (m, 3H),7.10 (dd, J = 8.5, 1.8 Hz,
1H), 6.91 (d, J = 8.3 Hz, 1H), 6.87 – 6.74 (m, 3H), 3.76 (s, 3H), 2.39 (s, 3H); 13C NMR (75
MHz, CDCl3) δ 159.69, 152.65, 144.29, 139.37, 138.20, 132.87, 131.36, 131.07, 130.24,
129.85, 129.75, 129.44, 126.62, 125.75, 123.88, 121.23, 114.38, 114.32, 105.96, 55.33,
21.35; HRMS (ESI) calcd for C23H19Cl2N2O+ 409.0869, found 409.0882 [M + H]+.
1-(3,4-Dichlorophenyl)-3,5-di-p-tolyl-1H-pyrazole (4h)—Off white solid, m.p.
129-130 °C; 1H NMR (300 MHz, CDCl3) δ 7.78 (d, J = 7.8 Hz, 2H), δ 7.63 (d, J = 2.7Hz,
2H), 7.34 (d, J = 8.6 Hz, 1H), 7.24 (d, J = 7.4 Hz, 2H), 7.20 – 7.13 (m, 4H), 7.08 (dd, J =
9.0, 2.7 Hz, 1H), 6.74 (s, 1H), 2.39 (s, 3H), 2.38 (s, 3H); 13C NMR (75 MHz, CDCl3) δ
152.62, 144.56, 139.50, 138.81, 138.12, 132.87, 130.99, 130.23, 129.85, 129.46, 129.42,
128.63, 127.18, 126.71, 125.75, 123.96, 105.68, 21.34, 21.33; HRMS (ESI) calcd for
C23H19Cl2N2 + 393.0920, found 393.0897 [M + H]+.
1-(3-Chloro-4-methylphenyl)-3,5-di-p-tolyl-1H-pyrazole (4i)—Off white solid, m.p.
96-97 °C; 1H NMR (300 MHz, CDCl3) δ 7.79 (d, J = 7.7 Hz, 2H), 7.52 (s, 1H), 7.23 (d, J =
8.2 Hz, 2H), 7.15 (q, J = 8.5 Hz, 5H), 7.03 (d, J = 8.0 Hz, 1H), 6.73 (s, 1H), 2.38 (s, 3H),
2.36 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 152.15, 144.41, 139.03, 138.41, 137.84, 135.10,
134.46, 130.72, 130.15, 129.35, 129.27, 128.60, 127.48, 125.72, 123.29, 105.03, 21.33,
21.30, 19.73; HRMS (ESI) calcd for C24H22ClN2 + 373.1466, found 373.1483 [M + H]+.
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1-(4-tert-Butylphenyl)-3,5-di-p-tolyl-1H-pyrazole (4j)—Off white solid, m.p. 160-161
°C; 1H NMR (300 MHz, CDCl3) δ 7.80 (d, J = 8.0 Hz, 2H), 7.37 (d, J = 8.6 Hz, 2H), 7.28
(d, J = 8.7 Hz, 2H), 7.21 – 7.16 (m, 4H), 7.11 (d, J = 8.1 Hz, 2H), 6.74 (s, 1H), 2.37 (s, 3H),
2.35 (s, 3H), 1.31 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 151.73, 150.35, 144.26, 138.04,
137.81, 137.59, 130.41, 129.30, 129.15, 128.59, 127.87, 125.82, 125.69, 124.79, 104.56,
31.35, 21.33, 21.30; HRMS (ESI) calcd for C27H29N2 + 381.2325, found 381.2327 [M +
H]+.
1-(4-tert-Butylphenyl)-3-(4-chlorophenyl)-5-(2-fluorophenyl)-1H-pyrazole (4k)—
Off white solid, m.p. 141-142 °C; 1H NMR (300 MHz, CDCl3) δ 7.85 (d, J = 8.2 Hz, 2H),
7.36 (dd, J = 14.7, 8.4 Hz, 5H), 7.29 – 7.18 (m, 3H), 7.16 – 7.03 (m, 2H), 6.83 (s, 20 1H),
1.30 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 161.19 , 157.88 , 150.65 (d, JC,F = 2.3 Hz),
138.05 , 137.58 , 133.65 , 131.75 , 131.20 , 130.61 (d, JC,F = 8.1 Hz), 128.80 , 127.04 ,
125.87 , 124.33, 123.78 , 118.78 (d, JC,F = 14.8 Hz), 116.28 , 116.00 , 106.44 (d, J = 2.0
Hz), 34.62 , 31.29; HRMS (ESI) calcd for C25H22ClFN2Na+ 427.1348, found 427.1351 [M
+ Na]+.
3-(4-Chlorophenyl)-5-(2-fluorophenyl)-1-o-tolyl-1H-pyrazole (4l)—Dark red solid,
m.p. 134-135 °C; 1H NMR (300 MHz, CDCl3) δ 7.83 (d, J = 8.5 Hz, 2H), 7.35 (d, J = 8.5
Hz, 2H), 7.25 – 7.12 (m, 5H), 7.08 – 6.92 (m, 3H), 6.86 (d, J = 1.2 Hz, 1H), 2.08 (s,
3H); 13C NMR (75 MHz, CDCl3) δ 161.15 (d, JC,F = 248.25 Hz), 150.72, 139.42, 139.14,
135.55, 133.67, 131.79, 131.16 , 130.66 (d, JC,F = 8.23 Hz), 129.02, 128.94 (d, JC,F = 12.2
Hz), 127.81, 127.12, 126.47, 124.04 (d, JC,F = 3.7 Hz), 118.31 (d, JC,F = 14.3 Hz), 116.23,
115.94 , 105.35 (d, JC,F = 3.2 Hz), 17.69; HRMS (ESI) calcd for C22H16ClFN2Na+
385.0878, found 385.0885 [M + Na]+.
1-(4-tert-Butylphenyl)-3-(4-methoxyphenyl)-5-(4-nitrophenyl)-1H-pyrazole (4m)
—Pale green solid, m.p. 134-135 °C; 1H NMR (300 MHz, CDCl3) δ 8.16 (d, J = 8.7 Hz,
2H), 7.84 (d, J = 8.7 Hz, 2H), 7.42 (dd, J = 12.6, 8.6 Hz, 4H), 7.28 – 7.21 (m, 2H), 6.96 (d, J
= 8.7 Hz, 2H), 6.85 (s, 1H), 3.85 (s, 3H), 1.33 (s, 9H); 13C NMR (75 MHz, CDCl3) δ
159.79, 152.04, 151.37, 147.21, 141.81, 137.11, 136.94, 129.18, 127.07, 126.26, 125.29,
124.92, 123.79, 114.12, 105.54, 55.32, 34.74, 31.30; HRMS (ESI) calcd for
C26H25N3NaO3 + 450.1788, found 450.1793 [M + Na]+.
1-(3-Chloro-4-methylphenyl)-3-(4-methoxyphenyl)-5-(4-nitrophenyl)-1H-
pyrazole (4n)—Pale green solid, m.p. 109-110 °C; 1H NMR (300 MHz, CDCl3) δ 8.19 (d,
J = 8.0 Hz, 2H), 7.83 (d, J = 7.9 Hz, 2H), 7.57 – 7.38 (m, 3H), 7.19 (d, J = 7.6 Hz, 1H), 6.97
(d, J = 7.6 Hz, 3H), 6.84 (s, 1H), 3.85 (s, 3H), 2.40 (s, 3H); 13C NMR (75 MHz, CDCl3) δ
159.94, 152.44, 147.38, 141.92, 138.32, 136.55, 136.16, 134.94, 131.14, 129.25, 127.13,
125.86, 125.01, 123.91, 123.38, 114.18, 106.02, 55.34, 19.78; HRMS (ESI) calcd for
C23H19ClN3O3 + 420.1109, found 420.1121 [M + H]+.
1-(4-Methoxyphenyl)-3,5-diphenyl-1H-pyrazole (4o)—Off white solid, m.p. 121-122
°C; 1H NMR (300 MHz, CDCl3) δ 7.91 (d, J = 7.6 Hz, 2H), 7.42 (t, J = 7.5 Hz, 2H), 7.36 –
7.25 (m, 8H), 6.86 (d, J = 8.9 Hz, 2H), 6.81 (s, 1H), 3.81 (s, 3H); 13C NMR (75 MHz,
CDCl3) δ 158.85, 151.63, 144.34, 133.45, 133.17, 130.62, 128.84, 128.63, 128.45, 128.17,
127.89, 126.75, 125.78, 114.11, 104.64, 55.50; HRMS (ESI) calcd for C22H18N2NaO+
349.1311, found 349.1298 [M + Na]+.
Cell Culture and Cell Proliferation Assay
Cell culture—Human ovarian adenocarcinoma cells (SK-OV-3), colon adenocarcinoma
(HT-29) and cervical adenocarcinoma (HeLa) were obtained from American Type Culture
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Collection. Cells were grown on 75 cm2 cell culture flasks with EMEM (Eagle’s minimum
essential medium), supplemented with 10% fetal bovine serum, and 1% penicillin/
streptomycin solution (10,000 units of penicillin and 10 mg of streptomycin in 0.9% NaCl)
in a humidified atmosphere of 5% CO2, 95% air at 37 °C.
Cell proliferation assay—Cell proliferation assay was carried out using CellTiter 96
aqueous one solution cell proliferation assay kit (Promega, USA). Briefly, upon reaching
about 75-80% confluency, 5000 cells/well were plated in 96-well microplate in 100 EL
media. After seeding for 72 h, the cells were treated with 50 EM compound in triplicate.
Doxorubicin (10 EM) was used as the positive control. At the end of the sample exposure
period (72 h), 20 EL CellTiter 96 aqueous solution was added. The plate was returned to the
incubator for 1 h in a humidified atmosphere at 37 °C. The absorbance of the formazan
product was measured at 490 nm using microplate reader. The blank control was recorded
by measuring the absorbance at 490 nm with wells containing medium mixed with CellTiter
96 aqueous solution but no cells. Results were expressed as the percentage of the control
(without compound set at 100%).
Conclusions
In summary, we have developed a simple, efficient and environmentally friendly protocol
for the synthesis of 1,3,5-triarylpyrazoles and 1,3,5-triarylpyrazolines in [bimm][PF6] ionic
liquid mediated by Cu(OTf)2. The reaction protocol exhibited tolerance with different
functional groups, generating pyrazoles in good to high yields (71-82%) without any
requirement for additional reagent for the oxidation of in situ generated pyrazolines. The
catalyst can be reused up to four cycles without much loss in catalytic activity. The
pyrazoles (4a-o) and pyrazolines (3a-n) were evaluated for antiproliferative activity.
Compound 3b inhibited cell proliferation of HeLa cells by 80% at a concentration of 50 μM.
All other synthesized derivatives exhibited a modest inhibition against the proliferation of
SK-OV-3, HT-29 and HeLa cells. Further structure-activity relationship studies are required
for optimizing antiproliferative activities of these classes of compounds.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1.
Chemical structure of drug molecules, celecoxib and rimonabant containing pyrazole
scaffold
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Fig. 2.
Antiproliferative activity of 4a-o
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Fig. 3.
Antiproliferative activity of 3a-n
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Scheme 1.
Synthesis of substituted 1,3,5-triarylpyrazoles
Rao et al. Page 14
RSC Adv. Author manuscript; available in PMC 2014 September 21.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Scheme 2.
Proposed mechanism for synthesis of 1,3,5-triarylpyrazole
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Table 1
Optimization of reaction conditions for the synthesis of 4a.a
S. No. Catalyst Mol (%) Solvent Yield (3a)(%)b
Yield (4a)
(%)b
1 Cu(OTf)2 10 [bmim][PF6] 15 64c
2 Cu(OTf)2 20 [bmim][PF6] - 82d,e
3 Cu(OTf)2 30 [bmim][PF6] - 84
4 Cu(OTf)2 20 [bmim][BF4] 35 50
5 Cu(OTf)2 20 [bmim][Br] 50 21
6 Cu(OTf)2 20 DMSO - 15
7 Cu(OTf)2 20 DMF - 33
8 Cu(OTf)2 20 Ethanol 62f -
9 Cu(OTf)2 20 PEG 60 -
10 Sc(OTf)3 20 [bmim][PF6] 61 19
11 Ce(OTf)3 20 [bmim][PF6] 75 10
12 pTSA 20 [bmim][PF6] 69 -
13 Zn(OTf)2 20 [bmim][PF6] 55 30
14 AgOTf 20 [bmim][PF6] 15 65
15 Yb(OTf)3 20 [bmim][PF6] 58 22
a
Reaction condition: Chalcone (1.0 mmol), arylhydrazine (1.2 mmol), catalyst (x mol%), solvent (2 mL), 130 °C, 2 h.
b
Isolated yield.
cOnly 20% of 3a was formed after 30 min in the absence of Cu(OTf)2 under similar conditions.
dAt 100 °C, complete conversion of 3a to 4a was not observed and it requires longer reaction time.
eWhen isolated 3a was used 95% yield of 4a was obtained.
f
Reflux condition.
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Table 2
Synthesized 1,3,5-triarylpyrazoles (4a-o)
Compd. R1 R2 R3 Time (h) Yield (%)a
4a H H 4-C(CH3)3 2 82b
4b H H 2-CH3 2 81
4c H H 3,4-Cl 3 80
4d H H 3-Cl, 4-CH3 2.5 72
4e 4-OMe H 3,4-Cl 2 71
4f 4-OMe H 3-Cl, 4-CH3 2 77
4g 3-OMe 4-CH3 3,4-Cl 2 79
4h 4-CH3 4-CH3 3,4-Cl 2 74
4i 4-CH3 4-CH3 3-Cl, 4-CH3 2 77
4j 4-CH3 4-CH3 4-C(CH3)3 1.5 77
4k 2-F 4-Cl 4-C(CH3)3 2 84
4l 2-F 4-Cl 2-CH3 2 82
4m 4-NO2 4-OMe 4-C(CH3)3 1 75
4n 4-NO2 4-OMe 3-Cl, 4-CH3 1 81
4o H H 4-OMe 1.5 78
a
Isolated yield.
b
In four consecutive recycle experiment 4a was observed in 82, 80, 78, and 79% yield, respectively.
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Table 3
Synthesized 1,3,5-triarylpyrazolines (3a-n)
Compd. R1 R2 R3 Time(Min.)
Yield
(%)a
3a H H 4-C(CH3)3 30 84
3b H H 2-CH3 30 66
3c H H 3,4-Cl 30 77
3d H H 3-Cl, 4-CH3 30 68
3e 4-OMe H 3,4-Cl 30 72
3f 4-OMe H 3-Cl, 4-CH3 30 78
3g 3-OMe 4-CH3 3,4-Cl 30 60
3h 4-CH3 4-CH3 3,4-Cl 30 72
3i 4-CH3 4-CH3 3-Cl, 4-CH3 30 74
3j 4-CH3 4-CH3 4-C(CH3)3 30 79
3k 2-F 4-Cl 4-C(CH3)3 30 63
3l 2-F 4-Cl 2-CH3 30 65
3m 4-NO2 4-OMe 4-C(CH3)3 20 72
3n 4-NO2 4-OMe 3-Cl, 4-CH3 20 80
a
Isolated yield.
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